SAN DIEGO–(BUSINESS WIRE)–Robbins Umeda LLP has begun investigating possible mismanagement of Stryker Corporation (“Stryker” or the “Company”) (NYSE: SYK). Stryker, a medical technology company, manufactures and sells medical devices, primarily orthopedic surgical implants, and medical equipment. Founded in 1941, the Company is headquartered in Kalamazoo, Michigan.
Robbins Umeda LLP’s investigation of Stryker concerns questionable statements issued by the Company between January 25, 2007 and November 13, 2008, regarding its business success and profitability as well as whether the Company cut corners on its operational costs by failing to document and maintain adequate quality controls over the products it manufactured. Company insiders took advantage of the stock’s 52-week high of $75 per share (split-adjusted) in November 2007, when they sold their personally-held shares generating more than $300 million in proceeds prior to the stock’s 52% decline to $36.11 on November 20, 2008.
A lawsuit alleging violations of the Securities Exchange Act of 1934 has been filed on behalf of shareholders who purchased or otherwise acquired Stryker stock between January 25, 2007 and November 13, 2008, seeking recovery from Stryker and certain of its officers for the damages they have suffered as a result of the officers’ mismanagement of the Company. Securities class actions like this can potentially cause additional damage to the Company.
If you purchased Stryker stock before January 25, 2007, continue to hold your shares, and would like more information about your rights as a shareholder, please contact attorney Lauren Levi at 800-350-6003 or by e-mail at email@example.com.
Robbins Umeda LLP is a California-based law firm with significant experience representing investors in shareholder derivative and securities fraud class actions. For more information about the firm, please visit our website at http://www.robbinsumeda.com.
Robbins Umeda LLP